| Literature DB >> 35886265 |
Lesli Álvarez-Millán1,2, Claudia Lerma3, Daniel Castillo-Castillo4, Rosa M Quispe-Siccha5, Argelia Pérez-Pacheco5, Jesús Rivera-Sánchez5, Ruben Fossion2,6.
Abstract
The frailty syndrome is characterized by a decreased capacity to adequately respond to stressors. One of the most impaired physiological systems is the autonomous nervous system, which can be assessed through heart rate (HR) variability (HRV) analysis. In this article, we studied the chronotropic response (HR and HRV) to a walking test. We also analyzed HRV indices in rest as potential biomarkers of frailty. For this, a 160 m-walking test and two standing rest tests (before and after the walking) were performed by young (19-29 years old, n = 21, 57% women), middle-aged (30-59 years old, n = 16, 62% women), and frail older adults (>60 years old, n = 28, 40% women) and non-frail older adults (>60 years old, n = 15, 71% women), classified with the FRAIL scale and the Clinical Frailty Scale (CFS). Frequency domain parameters better allowed to distinguish between frail and non-frail older adults (low-frequency power LF, high-frequency power HF (nu), LF/HF ratio, and ECG-derived respiration rate EDR). Frail older adults showed an increased HF (nu) and EDR and a reduced LF (nu) and LF/HF compared to non-frail older adults. The increase in HF (nu) could be due to a higher breathing effort. Our results showed that a walk of 160 m is a sufficient cardiovascular stressor to exhibit an attenuated autonomic response in frail older adults. Several HRV indices showed to be potential biomarkers of frailty, being LF (nu) and the time required to reach the maximum HR the best candidates.Entities:
Keywords: autonomic response; early biomarkers; heart rate dynamics; orthostatic stressor; stimulus-response paradigm
Mesh:
Year: 2022 PMID: 35886265 PMCID: PMC9320251 DOI: 10.3390/ijerph19148413
Source DB: PubMed Journal: Int J Environ Res Public Health ISSN: 1660-4601 Impact factor: 4.614
Demographic and most common comorbidities of the study participants. Results are reported as mean ± standard deviation or absolute value (percentage).
| Variables | C1 | C2 | nF | F |
|---|---|---|---|---|
| ( | ( | ( | ( | |
| Age (years) | 22.0 ± 1.4 | 48.6 ± 8.9 * | 71.5 ± 8.2 *,** | 78 ± 5.4 *,**,|| |
| Sex | ||||
| Male | 9 (43%) | 6 (38%) | 9 (60%) | 8 (29%) |
| Female | 12 (57%) | 10 (62%) | 6 (40%) | 20 (71%) |
| Body mass index (kg/m2) | 23.8 ± 3.6 | 27.5 ± 5.9 | 27.4 ± 3.6 * | 26.4 ± 3.9 * |
| Physical activity | ||||
| Mild | 9 (43%) | 8 (50%) | 0 (0%) | 2 (7%) |
| Moderate | 12 (57%) | 8 (50%) | 6 (40%) | 20 (71%) |
| Comorbidities | ||||
| Hypertension | 0 | 3 | 4 | 15 |
| Mild cognitive | 0 | 0 | 0 | 14 |
| Diabetes | 0 | 0 | 2 | 10 |
| Depression | 0 | 0 | 2 | 9 |
* p < 0.05 compared to C1; ** p < 0.05 compared to C2; || p < 0.05 compared to nF.
Figure 1Flow diagram of the study protocol. FRAIL = fatigue, resistance, ambulation, illness, and low performance scale; CFS = clinical frailty scale; HRV = heart rate variability; FFT = Fast Fourier Transform; PSD = power spectrum density; ROC = receiver operator characteristic.
Heart rate response ΔHR and linear HRV parameters evaluated from a 160-m walking test in young adults (C1), middle-aged adults (C2), non-frail older adults (nF), and frail older adults.
| C1 | C2 | nF | F | ||
|---|---|---|---|---|---|
|
| |||||
| HR (1/min) (bpm) | 81.2 (69.9–89.9) | 74.2 (65.1–84.4) | 76.4 (65.9–82.5) | 74.1 (67.2–84.5) | 0.462 |
| Mean RR (ms) | 747 (672–866) | 811 (713–924) | 788 (736–912) | 811 (721–908) | 0.540 |
| SDNN (ms) | 61.5 (46.7–76.4) | 48.6 (35.3–63.8) | 29.6 (27.6–46.7) **,|| | 33.2 (20.6–57.2) **,|| | 0.000 # |
| CV (%) | 82.5 (53.8–98.6) | 68.5 (46.8–102.0) | 42.9 (33.1–68.1) **,|| | 46.0 (26.5–88.6) ** | 0.007 # |
| RMSSD (ms) | 33.5 (25.5–42.1) | 27.9 (17.3–39.5) | 13.5 (7.7–25.7) **,|| | 22.4 (9.7–71.8) | 0.010 # |
| pNN30 (%) | 34.3 (24.6–45.1) | 22.4 (13.7–35.9) | 4.6 (1.2–32.6) ** | 3.7 (7.6–26.6) ** | 0.006 # |
| pNN50 (%) | 12 (3.00–22.00) | 6 (1.00–16.00) | 1 (0.00–7.00) **,|| | 2 (0.00–12.00) **,¶ | 0.004 # |
| LF (ms2) | 1202.5 (1066.2–1842.6) | 531.1 (473.5–1464.4) ** | 172.9 (74.5–916.0) **,|| | 167.8 (53.6–1041.0) **,|| | 0.000 # |
| HF (ms2) | 380.5 (247.1–1263.6) | 275.7 (176.9–617.7) | 67.5 (38.5–201.1) **,|| | 97.4 (186.8–2130.0) ** | 0.002 # |
| LF (nu) | 75.5 (64–85.5) | 74.0 (57.5–87.9) | 81.3 (69.0–89.3) | 59.8 (34.0–77.1) **,||,¶ | 0.011 # |
| HF (nu) | 24.0 (14.4–35.8) | 26.0 (12.0–42.4) | 18.6 (10.7–31.0) | 40.1 (22.9–64.9) **,||,¶ | 0.010 # |
| LF/HF | 3.14 (1.79–5.93) | 2.84 (1.35–7.33) | 4.38 (2.23–8.38) | 1.49 (0.52–3.37) **,||,¶ | 0.010 # |
| EDR (Hz) | 0.2 (0.16–0.21) | 0.18 (0.17–0.19) | 0.17 (0.14–0.19) | 0.19 (0.16–0.22) ¶ | 0.214 |
|
| |||||
| HR (1/min) | 77.2 (67.00–88.2) * | 75.5 (61.7–86.2) | 75.2 (66.0–79.5) | 78.6 (69.1–87.6) * | 0.582 |
| Mean RR (ms) | 786 (685–900) * | 811 (700–983) | 801 (757–914) | 766 (694–873) * | 0.619 |
| SDNN (ms) | 59.1 (52.6–82.4) | 51.2 (42.4–61.7) ** | 29.7 (19.1–37.2) **,|| | 28.0 (21.9–49.6) **,|| | 0.000 # |
| CV (%) | 75.5 (58.8–122.3) | 68.5 (49.0–96.4) | 39.6 (24.5–58.0) **,|| | 41.1 (24.6–72.3) **,|| | 0.000 # |
| RMSSD (ms) | 37.9 (29.7–46.1) | 35.1 (14.4–39.0) | 15.0 (12.5–21.9) **,|| | 16.5 (8.3–58.7) ** | 0.003 # |
| pNN30 (%) | 39.7 (30.5–51.5) | 30.7 (17.5–44.8) | 4.4 (1.7–18.2) **,|| | 2.8 (5.4–20.9) **,|| | 0.000 # |
| pNN50 (%) | 16.00 (10.00–26.00) * | 12.00 (1.00–20.00) | 0.00 (0.00–2.00) **,|| | 1.00 (0.00–22.00) ** | 0.000 # |
| LF (ms2) | 1564.1 (1234.8–2595.7) | 916.5 (617.3–1414.6) ** | 362.7 (180.6–646.5) **,|| | 138.1 (144.6–950.7) **,|| | 0.000 # |
| HF (ms2) | 601.2 (482.0–1301.4) | 319.9 (221.5–651.6) | 77.0 (21.9–259.9) **,|| | 65.3 (189.5–1066.9) ** | 0.001 # |
| LF (nu) | 73.3 (60.4–80.1) | 77.0 (45.1–89.4) | 81.5 (68.5–86.5) | 68.8 (42.6–77.6) ¶ | 0.098 |
| HF (nu) | 26.7 (19.6–39.5) | 23.0 (10.6–54.9) | 18.4 (13.4–31.1) | 31.3 (22.3–57.2) ¶ | 0.101 |
| LF/HF | 2.74 (1.53–4.08) | 3.35 (0.82–8.43) | 4.49 (2.20–6.44) | 2.19 (0.75–3.47) ¶ | 0.102 |
| EDR (Hz) | 0.19 (0.16–0.23) | 0.17 (0.16–0.19) | 0.17 (0.13–0.19) | 0.18 (0.16–0.22) | 0.431 |
| HR | |||||
|
| 39.0 (33.1–48.2) | 42 (29.8–59.6)) | 54 (26.3–84.7) | 115 (96.5–175.3) **,||,¶ | 0.000 # |
|
| 107.0 (101.4–114.4) | 104.2 (91.2–107.9) | 98.3 (90.9–103.4) ** | 88.3 (87.1–100.2) | 0.013 # |
|
| 2.4 (2.3–4.1) | 2.5 (1.5–5.1) | 1.8 (1.0–6.7) | 0.7 (0.6–1.9) **,||,¶ | 0.000 # |
| 20.0 (12.2– 24.9) | 16.5 (−11.3–28.6) | 16.4 (1.3–26.2) | 15.2 (8.6–23.1) | 0.734 | |
| −19.5 (−12.7–−23.3) | −15.9 (−10.1–−25.4) | −16.2 (−11.9–−26.2) | −8.8 (−5.0–36.9) **,||,¶ | 0.002 # | |
| −3.9 (−4.9–−0.9) | 0.1 (−2.8–3.4) | 0.4 (−4.3–3.4) | 4.3 (0.5–8.6) **,||,¶ | 0.001 # | |
n: number of participants. Data is shown as median (percentile 25–percentile 75). # p < 0.05 for Kruskal–Wallis test. * p < 0.05 compared to baseline (comparison between phases for the same group). ** p < 0.05 compared to C1 (comparison between groups for the same phase). || p < 0.05 compared to C2 (comparison between groups for the same phase). ¶ p < 0.05 compared to nF (comparison between groups for the same phase).
Non-linear HRV parameters evaluated from a 160-m walking test in young adults (C1), middle-aged adults (C2), non-frail older adults (nF), and frail older adults. n: number of participants. Data is shown as median (percentile 25 –percentile 75).
| C1 | C2 | Nf | F | ||
|---|---|---|---|---|---|
|
| |||||
| SD1 (ms) | 23.7 (18.0–29.8) | 19.8 (12.3–28.0) | 9.5 (5.4–18.2) **,|| | 15.9 (6.9–50.8) | 0.010 # |
| SD2 (ms) | 81.7 (64.3–104.1) | 67.0 (48.4–87.6) | 39.8 (38.4–63.1) **,|| | 39.8 (27.1–73.7) **,|| | 0.000 # |
| SD1/SD2 | 0.3 (0.2–0.4) | 0.3 (0.2–0.4) | 0.2 (0.2–0.3) | 0.3 (0.2–0.8) | 0.136 |
| ApEn | 1.11 (1.03–1.19) | 1.07 (1.03–1.13) | 1.04 (0.97–1.14) | 1.02 (0.95–1.11) ** | 0.149 |
| SampEn | 1.35 (1.18–1.63) | 1.27 (1.11–1.64) | 1.18 (1.03–1.51) | 1.16 (0.96–1.39) ||,¶ | 0.353 |
| α1 | 1.37 (1.16–1.47) | 1.40 (1.06–1.66) | 1.41 (1.26–1.57) | 1.08 (0.63–1.35) **,||,¶ | 0.006 # |
|
| |||||
| SD1 (ms) | 26.8 (21.0–32.7) | 24.9 (10.2–27.6) | 10.6 (8.9–15.5) **,|| | 11.7 (5.8–41.6) ** | 0.003 # |
| SD2 (ms) | 79.8 (68.8–109.9) | 71.7 (54.6–74.4) ** | 40.5 (26.5–51.5) **,|| | 38.5 (30.1–61.6) **,|| | 0.000 # |
| SD1/SD2 | 0.3 (0.2–0.4) | 0.3 (0.2–0.5) | 0.3 (0.2–0.4) | 0.3 (0.2–0.8) | 0.381 |
| ApEn | 1.12 (0.97–1.17) | 1.06 (0.92–1.12) | 1.12 (1.01–1.18) | 1.02 (0.91–1.13) | 0.184 |
| SampEn | 1.52 (1.25–1.67) | 1.22 (0.94–1.71) | 1.39 (1.14–1.69) * | 1.21 (0.96–1.37) **,¶ | 0.065 |
| α1 | 1.27 (1.09–1.37) * | 1.40 (0.88–1.54) | 1.37 (1.18–1.51) | 1.17 (0.79–1.32) ¶ | 0.075 |
# p < 0.05 for Kruskal–Wallis test. * p < 0.05 compared to baseline (comparison between phases for the same group). ** p < 0.05 compared to C1 (comparison between groups for the same phase). || p < 0.05 compared to C2 (comparison between groups for the same phase). ¶ p < 0.05 compared to nF (comparison between groups for the same phase).
Figure 2Heart rate time series from a selected (a) young adult, (b) a non-frail older adult and (c) a frail older adult during the whole test. The left fragment shaded in gray corresponds to the first 5 min of standing rest (baseline). The white part shows the fragment where participants walked a fixed distance of 160 m. Fragment sizes of walking are different as every person walked at their own preferred pace. The right gray shaded fragment corresponds with the recovery phase, which means 5 min of standing rest. Adapted with permission from Ref. [27]. 2022, AIP Publishing.
Figure 3Receiver-operator characteristic (ROC) curve (A) and scatter plot (B) of LF (nu) evaluated during 5 min of standing rest (baseline phase) in 15 non-frail and 27 frail older adults. The best cut-off point, indicated by symbol ‘x’ in panel (A), was determined according to the shortest orthogonal distance from each point to the optimum vale (0,1). The line in panel (B) indicates the cut-off point at 77.3 normalized units (nu).
Figure 4(a) Heart rate time series from young adults (group C1), non-frail older adults (group nF) and frail older adults (group F) during the whole test. Dashed vertical line represent the final of baseline phase (first 5 min). The final of the walking test cannot be specified as every subject walked to their own pace and traveled the fixed distance of 160 m in different times. (b) Chronotropic response ΔHR and changes in selected HRV parameters comparing recovery vs. baseline phases expressed as a percentage. Changes were calculated through Equation (1) for young (C1), middle-aged adults (C2), non-frail older adults (nF), and frail adults (F). Black dots in panel (b) represent the outliers of the data. ¶ p < 0.05 compared to C1 (comparison between groups). # p < 0.05 compared to C1 (comparison between groups).
ROC curve analysis of heart rate response (ΔHR) and heart rate variability indices.
| AUC (95% CI) | Best Cut off Value | ||
|---|---|---|---|
|
| |||
| pNN50 (%) | 0.583 (0.408–0.758) | 0.386 | 0.8 |
| LF (nu) | 0.765 (0.609–0.922) | 0.080 | 77.3 |
| HF (nu) | 0.768 (0.612–0.924) | 0.005 | 22.6 |
| LF/HF | 0.768 (0.612–0.924) | 0.005 | 3.4 |
| EDR (Hz) | 0.686 (0.526–0.847) | 0.051 | 0.2 |
| SampEn (beats) | 0.597 (0.420–0.774) | 0.090 | 1.2 |
| α1 | 0.745 (0.891–0.599) | 0.010 | 1.2 |
|
| |||
| LF (nu) | 0.722 (0.554–0.890) | 0.020 | 78.6 |
| HF (nu) | 0.722 (0.554–0.890) | 0.020 | 21.4 |
| LF/HF | 0.722 (0.554–0.890) | 0.020 | 3.7 |
| SampEn | 0.724 (0.564–0.885) | 0.019 | 1.3 |
| α1 | 0.717 (0.557–0.876) | 0.023 | 1.2 |
|
HR | |||
| Δt (s) | 0.807 (0.652–0.962) | 0.006 | 74 |
| 0.824 (0.678–0.970) | 0.000 | 1.2 | |
| ΔHRRB | 0.707 (0.544–0.870) | 0.083 | −3.8 |
Predictive values of HRV indexes in 28 frail and 15 non-frail older adults.
| Sensitivity (%) | Specificity (%) | PPV (%) | NPV (%) | |
|---|---|---|---|---|
|
| ||||
| pNN50 > 0.8% | 43 (25–61) | 43 (17–69) | 60 (39–81) | 27 (9–46) |
| LF < 77.3 nu | 82 (68–96) | 71 (48–95) | 85 (72–99) | 67 (43–91) |
| HF >22.6 nu | 18 (4–32) | 29 (5–52) | 33 (9–57) | 15 (1–28) |
| LF/HF > 3.4 | 82 (68–96) | 71 (48–95) | 85 (72–99) | 67 (43–91) |
| EDR (Hz) > 0.2 | 36 (18–53) | 36 (11–61) | 53 (30–75) | 22 (5–39) |
| SampEn > 1.2 | 54 (35–72) | 64 (39–89) | 75 (56–94) | 41 (20–61) |
| α1 > 1.2 | 61 (43–79) | 86 (67–104) | 89 (76–103) | 52 (32–73) |
|
| ||||
| LF < 78.6 nu | 79 (63–94) | 57 (31–83) | 79 (63–94) | 57 (31–83) |
| HF > 21.3 nu | 21 (6–37) | 43 (17–69) | 43 (17–69) | 21 (6–37) |
| LF/HF > 3.7 | 79 (63–94) | 57 (31–83) | 79 (63–94) | 57 (31–83) |
| SampEn > 1.3 | 71 (55–88) | 64 (39–89) | 80 (64–96) | 53 (29–77) |
| α1 > 1.2 | 64 (47–82) | 79 (57–100) | 86 (71–101) | 52 (31–74) |
|
HR | ||||
| Δt (s) | 81 (64–98) | 70 (42–98) | 85 (69–101) | 64 (35–92) |
| 76 (58–94) | 70 (42–98) | 84 (68–101) | 58 (30–86) | |
| ΔHR > −3.6 | 54 (35–72) | 86 (67–104) | 88 (73–104) | 48 (28–68) |